UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): November 9, 2006

ZIOPHARM Oncology, Inc.
(Exact name of registrant as specified in its charter)

Delaware	0-32353	84-1475642
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1180 Avenue of the Americas, 19th Floor
New York, NY 10036
(Address of principal executive offices) (Zip Code)

(646) 214-0700
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On November 9, 2006 and November 10, 2006, the Company issued the press releases attached hereto as Exhibits 99.1 and 99.2, which are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated November 9, 2006.

99.2 Press Release dated November 10, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.:
(Registrant)

Date: November 10, 2006

By: /s/ Richard E. Bagley

RICHARD E. BAGLEY, President, *Chief Operating Officer and Chief Financial Officer*

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated November 9, 2006
99.2	Press Release dated November 10, 2006

ZIOPHARM Announces New ZIO-101 Mechanism Data at EORTC-NCI-AACR

--Further Differentiates ZIO-101--

PRAGUE - November 9, 2006 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced the presentation today by Dr. Taghi Manshouri of the University of Texas M. D. Anderson Cancer Center of new mechanism data that further differentiates ZIO-101, a novel organic arsenic, from inorganic arsenic. The mechanism data indicate that certain cancer cells resistant to inorganic arsenic are sensitive to ZIO-101. The presentation was part of the 18th EORTC-NCI-AACR Symposium on "Molecular Targets, and Cancer Therapeutics" meeting held in Prague. ZIO-101 clinical data will be the subject of a separate presentation at this meeting on November 10th.

Dr. Manshouri's data show that the major intra-cellular target of arsenic is the mitochondria, an organelle responsible for the energy charge of the cell. Disruption of mitochondrial function leads to apoptosis and cell death. Based on this mechanism ZIO-101 induces more cancer cell killing than inorganic arsenic. In addition, preliminary data from this study suggest that different genes are regulated by ZIO-101 than inorganic arsenic.

ZIO-101 has now entered phase II study in advanced multiple myeloma. The Company anticipates initiating phase II trials in other hematological malignancies and solid tumors early in 2007 and is planning on filing an Investigational New Drug application with the U.S. Food and Drug Administration for oral administration of ZIO-101 in the first half of 2007.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

ZIOP-G

Contact:
Suzanne McKenna
Investors
(646) 214-0703

Tina Posterli
Media
(917) 322-2565
tposterli@rxir.com

ZIOPHARM Announces Positive ZIO-101 Clinical Data at EORTC-NCI-AACR

--Phase II Trials Underway--

PRAGUE - November 10, 2006 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation by Luis Camacho, MD of the University of Texas M. D. Anderson Cancer Center of positive phase I clinical data for ZIO-101, an organic arsenic, from trials in both hematological cancers and solid tumors. Clinical activity was seen over a range of doses and ZIO-101 has now entered phase II trials. The poster was part of the 18th EORTC-NCI-AACR Symposium on "Molecular Targets, and Cancer Therapeutics" held in Prague.

Of the total 53 patients treated, 29 had diverse advanced solid tumors and 24 had blood and bone marrow cancers. There was clinical activity in 13 of 43 (30%) evaluable patients reported today. Clinical and pharmacokinetic data show that ZIO-101 is safe at doses up to 420mg/m^2/d for five consecutive days every four weeks. The major dose limiting toxicity was transient and reversible confusion/ataxia. ZIO-101 did not evidence QT prolongation and other toxicities seen with inorganic arsenic (Trisenox®).

Phase II trials have started in multiple myeloma. Phase II trials in other hematologic cancers and in liver cancer are expected to initiate early in 2007. The filing of an Investigational New Drug application with the U. S. Food and Drug Administration for an oral form of ZIO-101 is anticipated in the first half of 2007 with a phase I clinical trial expected to initiate soon thereafter.

"We see a strong signal of clinical activity in these early phase I studies," commented Dr. Brian Schwartz, Chief Medical Officer at ZIOPHARM. "The fact that this activity is evident over a range of doses in a variety of cancers, coupled with the growing body of pharmacokinetic data provides us with ample ammunition to explore this drug in phase II trials."

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

ZIOP-G

Contact:
Suzanne McKenna
ZIOPHARM Investor Relations
Investors
(646) 214-0703
smckenna@ziopharm.com

Tina Posterli
Rx Communications
Media
(917) 322-2565
tposterli@rxir.com